Q3 2019 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Ladies and gentlemen, welcome to the Sobi presentation of the Q3 results. (Operator Instructions)
I will now hand the call over to Guido Oelkers, CEO; and Henrik Stenqvist, CFO. Please go ahead.
()-&
Yes. Thank you so much, and welcome, everybody. Really pleasure to familiarize you with our Q3 results. You have seen this. And I think without further discussion, let's go straight in the meat.
Forward-looking statement, please take note of this. And with this, I go straight to Slide #4.
And when you look at the results, I think we are quite gratified by the fact, 27% top line growth, 18% EBITA growth, very pleased with the performance of Elocta and Alprolix. And for those who have seen some news, we sell Elocta and not ELOCTATE. And very, very gratified by the performance in over 30% for the quarter and over 40% for both products year-to-date and very strong patient growth.
And when you look at Gamifant, we are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
